Last reviewed · How we verify

NCT07509996

Risk Factors Affecting Growth in Thalassemic Children at AUCH

Not yet recruiting Last updated 3 April 2026
What this trial tests

trial testing Non-interventional assessment of growth and risk factors in thalassemic children in Thalassemia Majors (Beta-Thalassemia Major) in 85 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
1 April 2027
1 May 2027

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment85
Start date1 April 2026
Primary completion1 April 2027
Estimated completion1 May 2027

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 12 Months to 18, any sex, with Thalassemia Majors (Beta-Thalassemia Major). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thalassemia Majors (Beta-Thalassemia Major)

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing